In a CME session through your local dermatology society, a prominent drug company provides journal articles documenting the off-label use of one of their prescription pharmaceutical agents. You obtain CME credits, read the journal article and begin prescribing the off-label medication. Is the drug company in violation of the U.S. Food and Drug Administration (FDA) rulings? Are your actions acceptable?

I prescribe drugs off-label. Am I in violation of FDA regulations

In this article, Dr. Norman Levine sums up his takeaways from the American Academy of Dermatology annual meeting, beginning with a presentation by two physicians who addressed the difficulties of managing hidradenitis suppurativa, such as fixed dosing. He also addressed controversies associated with treatments for atopic dermatitis. Apparently, bleach baths are no better than regular baths in improving skin symptoms.

AAD insights and takeaways

Mounting clinical evidence points to a need for tighter disease control in psoriasis patients, says Dr. Alexander Egeberg.

The evolution of psoriasis from skin to heart disease

Dermatologists should take ownership of screening patients for mental health concerns associated with their skin condition.

Dermatologists fail to screen patients for depression

Study finds that second-line agents need to be incorporated into treatment for moderate to severe dermatomyositis, which is otherwise very difficult to treat.

Vol. 39 No. 03